medrxiv
preprint
viral
rna
clear
patient
within
day
ill
onset
use
antivir
drug
chloroquin
oseltamivir
arbidol
lopinavirritonavir
shorten
viral
rna
clearanc
especi
nonseri
case
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
background
novel
coronaviru
diseas
character
respiratori
symptom
becom
global
pandem
although
factor
influenc
viral
rna
clearanc
remain
unclear
inform
optim
isol
period
treatment
strategi
retrospect
studi
includ
patient
confirm
associ
clinic
characterist
treatment
regimen
time
viral
rna
clearanc
analyz
examin
consecut
case
account
confirm
case
guangzhou
period
time
report
th
march
recov
discharg
hospit
median
hospit
stay
day
interquartil
rang
iqr
overal
patient
achiev
viral
rna
clearanc
median
length
day
iqr
onset
ill
amongst
viral
rna
clear
within
day
within
day
older
age
sever
diseas
time
lag
ill
onset
hospit
admiss
high
bodi
temperatur
corticosteroid
use
associ
delay
clearanc
viral
rna
none
antivir
regimen
chloroquin
oseltamivir
arbidol
lopinavirritonavir
improv
viral
rna
clearanc
use
lopinavirritonavir
associ
delay
clearanc
viral
rna
adjust
confound
patient
isol
minimum
day
onset
ill
may
warrant
use
antivir
drug
enhanc
viral
rna
clearanc
end
new
type
pneumonia
caus
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
also
known
first
broke
wuhan
spread
rapidli
throughout
china
becam
global
pandem
infect
peopl
worldwid
caus
death
pose
enorm
challeng
global
public
health
date
sever
epidemiolog
studi
report
clinic
characterist
studi
larg
sampl
size
came
wuhan
center
outbreak
sudden
surg
demand
medic
care
influenc
time
treatment
result
seriou
ill
studi
patient
low
incid
area
may
provid
addit
insight
clinic
cours
patient
viral
rna
dose
determin
patient
infect
key
criterion
determin
period
isol
time
discharg
hospit
antivir
drug
specif
target
use
antivir
drug
approv
condit
larg
empir
patient
antivir
drug
chloroquin
arbidol
lopinavirritonavir
investig
smallscal
studi
recommend
option
antivir
regimen
china
countri
howev
efficaci
antivir
drug
rna
clearanc
remain
larg
unknown
guangzhou
denselypopul
metropolitan
citi
southern
china
guangzhou
heavili
hit
sar
lesson
learn
sar
provid
experi
manag
th
januari
th
march
patient
guangzhou
eighth
peopl
hospit
th
januari
th
march
hospit
respons
admit
major
confirm
case
guangzhou
area
patient
admit
outpati
clinic
transfer
hospit
confirm
case
even
asymptomat
isol
viral
rna
test
becam
neg
studi
approv
ethic
committe
eighth
hospit
guangzhou
patient
gave
written
inform
consent
infect
confirm
posit
rna
test
respiratori
tract
sampl
use
realtim
rtpcr
method
accord
manufactur
protocol
daan
gene
co
ltd
guangzhou
china
symptomat
patient
ill
onset
date
defin
date
symptom
eg
fever
cough
first
appear
asymptomat
patient
date
first
posit
rtpcr
test
defin
ill
onset
date
accord
chines
guidelin
sever
infect
group
four
categori
mild
moder
seriou
critic
ill
patient
mild
ill
chest
comput
tomographi
ct
find
moder
ill
featur
pneumonia
chest
ct
symptom
mild
seriou
ill
defin
presenc
least
one
follow
criteria
breath
rate
ii
puls
oximet
oxygen
satur
sao
rest
iii
ratio
partial
pressur
arteri
oxygen
pao
fraction
inspir
oxygen
fio
critic
ill
defin
presenc
least
one
follow
criteria
occurr
respiratori
failur
requir
mechan
ventil
ii
shock
iii
failur
organ
requir
treatment
intens
care
unit
icu
studi
group
patient
asymptomat
throughout
whole
clinic
cours
although
featur
pneumonia
chest
ct
distinguish
patient
defin
asymptomat
patient
patient
fulfil
follow
criteria
discharg
afebril
day
ii
improv
respiratori
symptom
iii
resolut
infiltr
shadow
pulmonari
imag
iv
clearanc
viral
rna
latter
defin
nuclear
acid
test
neg
least
two
sequenti
respiratori
tract
sampl
collect
h
interv
studi
viral
rna
test
respiratori
tract
sampl
repeat
everi
day
sinc
admiss
first
neg
test
date
sequenti
neg
test
defin
viral
rna
clear
day
record
patient
infect
extract
hospit
electron
medic
system
demograph
clinic
laboratori
imag
treatment
data
collect
review
train
physician
statist
analysi
perform
use
ibm
spss
statist
continu
variabl
express
median
interquartil
rang
iqr
categor
variabl
express
number
nonparametr
test
continu
data
ordin
data
chitest
categor
data
use
betweengroup
comparison
kaplanmei
curv
logrank
test
use
evalu
impact
demograph
clinic
factor
time
viral
rna
clearanc
hospit
stay
cox
regress
use
control
confound
factor
logist
regress
use
evalu
effect
antivir
regimen
clearanc
rate
p
valu
consid
statist
signific
overal
patient
infect
includ
studi
account
patient
guangzhou
report
period
tabl
median
age
year
old
iqr
patient
adolesc
age
year
old
total
patient
male
patient
smoker
median
incub
period
day
iqr
median
interv
ill
onset
hospit
admiss
day
iqr
among
patient
histori
exposur
area
epicent
hubei
provinc
close
contact
peopl
hubei
patient
least
one
comorbid
includ
hypertens
diabet
cardiovascular
diseas
malign
fever
cough
common
symptom
major
patient
normal
bodi
temperatur
time
hospit
admiss
laboratori
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
find
describ
tabl
half
patient
elev
ddimer
level
elev
procalcitonin
level
accord
sever
clinic
manifest
chest
imag
patient
categor
mild
moder
seriou
critic
ill
respect
patient
asymptomat
throughout
whole
clinic
cours
although
pneumonia
ct
imag
admiss
signific
differ
observ
diseas
sever
sex
smoke
statu
elderli
patient
comorbid
like
seriou
critic
ill
tabl
major
patient
receiv
antibiot
treatment
oxygen
therapi
four
patient
receiv
mechan
ventil
patient
admit
icu
total
patient
receiv
chloroquin
patient
treat
antivir
drug
oseltamivir
lopinavirritonavir
arbidol
respect
thirtyon
patient
treat
corticosteroid
patient
receiv
immunoglobulin
patient
receiv
ribavirin
tabl
four
three
critic
one
moder
patient
transfer
hospit
three
two
moder
one
seriou
patient
still
recov
hospit
compar
time
viral
rna
clearanc
demograph
clinic
characterist
shown
tabl
tabl
time
lag
ill
onset
hospit
admiss
old
age
diseas
sever
high
bodi
temperatur
corticosteroid
use
associ
delay
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
viral
rna
clearanc
breath
short
elev
white
blood
cell
count
reduc
serum
albumin
oxygen
therapi
immunoglobulin
use
also
associ
delay
viral
rna
clearanc
howev
associ
becam
insignific
adjust
age
diseas
sever
time
lag
ill
onset
hospit
admiss
signific
associ
sex
smoke
statu
comorbid
diseas
diseas
symptom
observ
tabl
tabl
specif
guidelin
indic
use
antivir
drug
compar
effect
differ
antivir
drug
combin
chloroquin
oseltamivir
arbidol
lopinavirritonavir
viral
rna
clearanc
shown
tabl
patient
receiv
antivir
drug
median
durat
day
iqr
ill
onset
day
iqr
hospit
admiss
viral
rna
clearanc
use
antivir
drug
monotherapi
combin
associ
improv
clearanc
viral
rna
compar
receiv
antivir
drug
patient
treat
lopinavirritonavir
combin
therapi
treat
hiv
infect
tend
delay
viral
rna
clearanc
even
control
age
diseas
sever
time
lag
ill
onset
hospit
admiss
temperatur
corticosteroid
use
combin
use
two
antivir
agent
also
associ
delay
clearanc
viral
rna
adjust
confound
analysi
focus
patient
moder
ill
yield
similar
result
tabl
figur
retrospect
studi
patient
covid
achiev
viral
rna
clearanc
within
day
time
lag
ill
onset
hospit
admiss
old
age
diseas
sever
high
bodi
temperatur
corticosteroid
use
associ
delay
clearanc
viral
rna
use
antivir
drug
chloroquin
oseltamivir
arbidol
lopinavirritonavir
benefit
clearanc
adjust
confound
use
lopinavirritonavir
combin
two
antivir
drug
tend
delay
clearanc
viral
rna
studi
median
time
ill
onset
viral
rna
clearanc
day
compar
day
report
patient
wuhan
might
reflect
sever
natur
latter
patient
current
consensu
deisol
manag
patient
especi
asymptomat
subject
high
risk
infect
cohort
patient
achiev
viral
rna
clearanc
within
day
within
day
specif
asymptomat
patient
achiev
viral
rna
clearanc
within
day
data
suggest
isol
least
day
onset
symptom
first
posit
pcr
test
warrant
patient
without
improv
symptom
drug
recommend
treatment
hospit
patient
china
countri
studi
patient
treat
chloroquin
appear
improv
viral
rna
clearanc
compar
support
treatment
larg
scale
random
control
studi
need
confirm
benefit
lopinavirritonavir
fix
dose
combin
antihiv
proteas
inhibitor
act
viral
proteas
although
use
treat
benefit
confirm
clinic
trial
involv
patient
pneumonia
wuhan
studi
apart
lack
benefit
use
lopinavir
ritonavir
tend
delay
viral
rna
clearanc
even
adjust
factor
includ
diseas
sever
arbidol
antivir
drug
approv
russia
china
treat
influenza
act
influenza
b
inhibit
viral
fusion
cellular
membran
block
viru
entri
host
cell
retrospect
cohort
studi
arbidol
acceler
clearanc
viral
rna
patient
compar
empir
treatment
china
recommend
one
antivir
drug
oseltamivir
anoth
drug
approv
treatment
influenza
b
use
patient
studi
neither
arbidol
oseltamivir
exhibit
posit
effect
viral
rna
clearanc
combin
arbidol
anoth
antivir
drug
oseltamivir
lopinavirritonavir
tend
delay
clearanc
viral
rna
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
patient
receiv
corticosteroid
treatment
compar
report
patient
wuhan
analysi
indic
corticosteroid
use
associ
delay
viral
rna
clearanc
line
recent
report
wuhan
may
due
select
bia
sinc
patient
seriouscrit
ill
like
treat
corticosteroid
moreov
corticosteroid
suppress
immun
systemand
delay
clearanc
viral
rna
call
cautiou
use
patient
older
age
diseas
sever
major
determin
persist
viral
rna
immun
system
weaken
age
diseas
sever
reflect
host
immun
inde
patient
age
year
old
seriou
critic
ill
public
health
measur
social
distanc
widespread
test
quarantin
contact
trace
reduc
spread
also
allow
earli
detect
patient
mild
diseas
time
support
treatment
help
reduc
burden
healthcar
system
treat
patient
seriou
ill
reduc
morbid
mortal
rate
guangzhou
increas
vigil
initi
outbreak
measur
togeth
adequ
medic
facil
support
mortal
rate
less
compar
earli
phase
outbreak
wuhan
limit
studi
first
due
small
sampl
size
data
regard
treatment
efficaci
antivir
drug
interpret
caution
second
patient
predomin
mild
moder
ill
result
may
appli
seriou
critic
ill
third
rtpcr
test
use
detect
viral
nuclear
acid
studi
may
sensit
enough
detect
sampl
low
viral
load
possibl
falseneg
result
fourth
viral
rna
test
repeat
everi
day
hospit
therefor
time
viral
rna
clearanc
may
littl
bia
lastli
retrospect
singlecent
studi
largescal
prospect
studi
need
confirm
find
conclus
patient
minimum
day
isol
sinc
ill
onset
may
warrant
even
asymptomat
patient
old
peopl
like
seriou
ill
delay
clearanc
viral
rna
may
requir
prolong
period
support
isol
use
antivir
drug
chloroquin
oseltamivir
arbidol
lopinavirritonavir
improv
viral
rna
clearanc
corticosteroid
use
associ
delay
clearanc
viral
rna
use
caution
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
c
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
data
present
number
categor
variabl
median
interquartil
rang
continu
variabl
four
patient
inform
viral
rna
clearanc
exclud
betweengroup
analysi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
remain
signific
p
adjust
age
sever
diseas
time
lag
ill
onset
hospit
admiss
becam
insignific
adjust
age
sever
diseas
time
lag
ill
onset
hospit
admiss
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
nonparametr
test
sever
rank
variabl
use
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
logrank
test
use
compar
differ
time
clearanc
p
univari
analysi
adjust
age
diseas
sever
time
lag
ill
onset
hospit
admiss
coxregress
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
model
hazard
ratio
adjust
age
diseas
sever
time
lag
ill
onset
hospit
admiss
bodi
temperatur
corticosteroid
use
model
hazard
ratio
adjust
age
time
sinc
ill
onset
hospit
admiss
bodi
temperatur
corticosteroid
use
